Childress Capital Advisors LLC Cuts Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Childress Capital Advisors LLC lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 5,654 shares of the company’s stock after selling 126 shares during the period. Childress Capital Advisors LLC’s holdings in IDEXX Laboratories were worth $2,337,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. FSA Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. boosted its position in IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after purchasing an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $31,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter valued at about $37,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on IDXX shares. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Barclays cut their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Piper Sandler reiterated a “neutral” rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Morgan Stanley dropped their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Finally, Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $517.29.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $469.04 on Tuesday. The stock has a 50-day moving average of $424.12 and a two-hundred day moving average of $453.55. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The stock has a market cap of $38.41 billion, a P/E ratio of 45.23, a P/E/G ratio of 3.64 and a beta of 1.37. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 2.18% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.